<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03422</article-id><article-id pub-id-type="doi">10.7554/eLife.03422</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group></article-categories><title-group><article-title>Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-14563"><name><surname>Kumari</surname><given-names>Snehlata</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-14564"><name><surname>Redouane</surname><given-names>Younes</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-2307"><name><surname>Lopez-Mosqueda</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-14569"><name><surname>Shiraishi</surname><given-names>Ryoko</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-14566"><name><surname>Romanowska</surname><given-names>Malgorzata</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-14565"><name><surname>Lutzmayer</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-14568"><name><surname>Kuiper</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-19519"><name><surname>Martinez</surname><given-names>Conception</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1078"><name><surname>Dikic</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-14570"><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="other" rid="par-12"/><xref ref-type="other" rid="par-13"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-14174"><name><surname>Ikeda</surname><given-names>Fumiyo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Institute for Genetics, Center for Molecular Medicine</institution>, <institution>University of Cologne</institution>, <addr-line><named-content content-type="city">Cologne</named-content></addr-line>, <country>Germany</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases</institution>, <institution>University of Cologne</institution>, <addr-line><named-content content-type="city">Cologne</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><label>3</label><institution>Institute of Molecular Biotechnology</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Institute of Biochemistry II</institution>, <institution>Goethe University Medical School</institution>, <addr-line><named-content content-type="city">Frankfurt am Main</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shao</surname><given-names>Feng</given-names></name><role>Reviewing editor</role><aff><institution>National Institute of Biological Sciences</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>ivan.dikic@biochem2.de</email> (ID);</corresp><corresp id="cor2"><email>pasparakis@uni-koeln.de</email> (MP);</corresp><corresp id="cor3"><email>fumiyo.ikeda@imba.oeaw.ac.at</email> (FI)</corresp><fn fn-type="con" id="equal-contrib"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>3</volume><elocation-id>e03422</elocation-id><history><date date-type="received"><day>21</day><month>05</month><year>2014</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Kumari et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Kumari et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-03422-v1.pdf"/><related-article ext-link-type="doi" related-article-type="article-reference" xlink:href="10.7554/eLife.03464"/><abstract><object-id pub-id-type="doi">10.7554/eLife.03422.001</object-id><p>Linear Ubiquitin chain Assembly Complex (LUBAC) is an E3 ligase complex that generates linear ubiquitin chains and is important for tumour necrosis factor (TNF) signaling activation. Mice lacking Sharpin, a critical subunit of LUBAC, spontaneously develop inflammatory lesions in the skin and other organs. Here we show that TNF receptor 1 (TNFR1)-associated death domain (TRADD)-dependent TNFR1 signaling in epidermal keratinocytes drives skin inflammation in Sharpin-deficient mice. Epidermis-restricted  ablation of Fas-associated protein with death domain (FADD) combined with receptor-interacting protein kinase 3 (RIPK3) deficiency fully prevented skin inflammation, while single RIPK3 deficiency only delayed and partly ameliorated lesion development in Sharpin-deficient mice, showing that inflammation is primarily driven by TRADD- and FADD-dependent keratinocyte apoptosis while necroptosis plays a minor role. At the cellular level, Sharpin deficiency sensitized primary murine keratinocytes, human keratinocytes, and mouse embryonic fibroblasts to TNF-induced apoptosis. Depletion of FADD or TRADD in Sharpin-deficient HaCaT cells suppressed TNF-induced apoptosis, indicating the importance of FADD and TRADD in Sharpin-dependent anti-apoptosis signaling in keratinocytes.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.001">http://dx.doi.org/10.7554/eLife.03422.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.03422.002</object-id><title>eLife digest</title><p>In response to an injury or an infection, areas of the body can become inflamed as the immune system attempts to repair the damage and/or destroy any microbes or toxins that have entered the body. At the level of individual cells inflammation can involve cells being programmed to die in one of two ways: apoptosis and necroptosis.</p><p>Apoptosis is a highly controlled process during which the contents of the cell are safely destroyed in order to prevent damage to surrounding cells. Necroptosis, on the other hand, is not controlled: the cell bursts and releases its contents into the surroundings.</p><p>Inflammation is activated by a protein called TNF, which is controlled by a complex that includes a protein called Sharpin. Mice that lack the Sharpin protein develop inflammation on the skin and other organs, even in the absence of injury or infection. However, it is not clear how the Sharpin protein controls TNF to prevent inflammation.</p><p>Kumari et al. have found that inflammation in mice lacking Sharpin depends on TNF interacting with another protein called TRADD. The experiments also show that the inflammation is mainly driven by apoptosis, with necroptosis having only a minor role. Further experiments carried out in mammal cells showed that TRADD and another protein (called FADD) work with Sharpin to prevent apoptosis.</p><p>At the molecular level, Sharpin is known to induce a special type of protein modification (called linear ubiquitination) with two partner proteins, so the next challenge is to work out exactly how Sharpin uses this process to prevent apoptosis.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.002">http://dx.doi.org/10.7554/eLife.03422.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>ubiquitin</kwd><kwd>TNFR1</kwd><kwd>Sharpin</kwd><kwd>skin inflammation</kwd><kwd>apoptosis</kwd><kwd>LUBAC</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P25508</award-id><principal-award-recipient><name><surname>Ikeda</surname><given-names>Fumiyo</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>250241</award-id><principal-award-recipient><name><surname>Dikic</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003072</institution-id><institution>LOEWE Zentrum AdRIA</institution></institution-wrap></funding-source><award-id>Ub-Net</award-id><principal-award-recipient><name><surname>Dikic</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB670</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>223404</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Deutsche Krebshilfe</institution></institution-wrap></funding-source><award-id>110302</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003042</institution-id><institution>Else Kröner-Fresenius-Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001656</institution-id><institution>Helmholtz Association</institution></institution-wrap></funding-source><award-id>Helmholtz Alliance Preclinical Comprehensive Cancer Center</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000854</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lopez-Mosqueda</surname><given-names>Jaime</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>2012-ADG_20120314</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>223151</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB829</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><award-group id="par-13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SPP1656</award-id><principal-award-recipient><name><surname>Pasparakis</surname><given-names>Manolis</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The adaptor proteins FADD and TRADD play an important role in the Sharpin-dependent anti-apoptosis signaling pathway in keratinocytes and regulate skin homeostasis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tumor necrosis factor receptor 1 (TNFR1)-mediated signaling is regulated by multiple ubiquitination events involving linear (Met1), Lys63 and Lys48 ubiquitination of several target proteins (<xref ref-type="bibr" rid="bib39">Wertz and Dixit, 2008</xref>; <xref ref-type="bibr" rid="bib37">Verhelst et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Schmukle and Walczak, 2012</xref>). Upon TNF stimulation, a receptor proximal signaling complex (termed complex I) consisting of the TNFR1-associated death domain (TRADD), receptor-interacting protein kinase 1 (RIPK1), TNF receptor-associated factor 2 (TRAF2), and cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) is recruited to the intracellular domain of TNFR1 (<xref ref-type="bibr" rid="bib7">Haas et al., 2009</xref>). Ubiquitination of proteins in complex I, including RIPK1, cIAP1/2, and TRAF2, leads to the recruitment of additional signaling components that facilitate activation of nuclear factor-κB (NF-κB) and mitogen-activated protein (MAP) kinase signaling cascades (<xref ref-type="bibr" rid="bib40">Wu et al., 2005</xref>; <xref ref-type="bibr" rid="bib36">Varfolomeev et al., 2008</xref>; <xref ref-type="bibr" rid="bib7">Haas et al., 2009</xref>). It has been shown that the transforming growth factor beta-activated kinase 1 (TAK1)/TAK1-binding protein 2 (TAB2) complex is recruited into complex I through the interaction between the TAB2-Npl4 zinc finger (NZF) and Lys63-linked ubiquitin chains (<xref ref-type="bibr" rid="bib11">Kanayama et al., 2004</xref>; <xref ref-type="bibr" rid="bib14">Kulathu et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Sato et al., 2009</xref>). cIAP-mediated ubiquitination of RIPK1 and cIAPs themselves was shown to result in the recruitment of the E3 ligase complex Linear Ubiquitin chain Assembly Complex (LUBAC) (<xref ref-type="bibr" rid="bib7">Haas et al., 2009</xref>) into complex I. LUBAC consists of a catalytic protein, HOIL-1L interacting protein (HOIP)/ring finger protein 31 (Rnf31), and two other critical subunits, Sharpin/Shank-interacting protein-like 1 (SIPL1) and HOIL-1L/RanBP-type and C3HC4-type zinc finger containing 1 (Rbck1) (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Tokunaga et al., 2011</xref>). Using biochemical and cell biological approaches, LUBAC has been shown to specifically generate linear ubiquitin chains, linked via Met1, and these chain types are important for pathway activation (<xref ref-type="bibr" rid="bib12">Kirisako et al., 2006</xref>). To date, LUBAC is the only E3 ligase complex identified that catalyzes linear ubiquitin chain generation. HOIP belongs to a RING-in-between-RING (RBR)-type of E3 ligase family and constitutes the catalytic center in LUBAC (<xref ref-type="bibr" rid="bib12">Kirisako et al., 2006</xref>; <xref ref-type="bibr" rid="bib31">Stieglitz et al., 2013</xref>). Interestingly, HOIP requires binding to either Sharpin or HOIL-1L for its catalytic action (<xref ref-type="bibr" rid="bib12">Kirisako et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Tokunaga et al., 2011</xref>; <xref ref-type="bibr" rid="bib30">Stieglitz et al., 2012</xref>). It was shown that the LUBAC-mediated ubiquitination of NEMO in the IκB kinase (IKK) complex is critical for the NF-κB signaling pathway. Sharpin or HOIL-1L deficiency partially suppress TNFR1-induced NF-κB activation, suggesting that these components show some degree of functional redundancy in regulating NF-κB signaling (<xref ref-type="bibr" rid="bib7">Haas et al., 2009</xref>; <xref ref-type="bibr" rid="bib33">Tokunaga et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Tokunaga et al., 2011</xref>).</p><p>Earlier studies identified Sharpin as the gene mutated in the chronic proliferative dermatitis mice (<italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>), which spontaneously develop severe chronic inflammation primarily in the skin but also in other tissues such as the gut, lung, liver, and esophagus (<xref ref-type="bibr" rid="bib6">Gijbels et al., 1996</xref>; <xref ref-type="bibr" rid="bib29">Seymour et al., 2007</xref>). The pathogenesis of multi-organ chronic inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice depends on TNF, as double <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnf</italic><sup>−/−</sup> mice did not develop signs of inflammatory skin and liver disease (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>). These results showed that Sharpin has an essential function in preventing TNF-induced chronic inflammation. However, the molecular mechanisms that are controlled by Sharpin to prevent TNF-induced inflammatory disease remain poorly understood. Here we show that the skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice is triggered by TNFR1-mediated TRADD- and FADD-dependent apoptosis of keratinocytes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TNFR1 deficiency in keratinocytes prevents skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice</title><p>Previous studies showed that TNF is required for the development of multi-organ inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>). To address whether this function of TNF is mediated by TNFR1, we crossed <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice with <italic>Tnfrsf1a</italic><sup>−/−</sup> animals. Double deficient <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup>−/−</sup> mice did not develop skin inflammation, demonstrating that TNF-induced TNFR1 signaling is essential for the pathogenesis of inflammatory skin lesions in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice (<xref ref-type="fig" rid="fig1">Figure 1</xref>). We then tried to identify the cellular target of the pathogenic TNFR1 signaling in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. We have recently shown that TNFR1 signaling in NF-κB-deficient epidermal keratinocytes drives psoriasis-like skin inflammation in mice (<xref ref-type="bibr" rid="bib15">Kumari et al., 2013</xref>), identifying keratinocytes as an important cellular target of pathogenic TNF signaling in skin inflammation. To address whether TNFR1 signaling in epidermal keratinocytes drives the skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, we crossed <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice with <italic>K14Cre</italic>-<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup> (TNFR1<sup>E-KO</sup>) mice that lack TNFR1 specifically in keratinocytes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). These <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice did not develop any macroscopic signs of skin inflammation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In addition, histological analysis of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice skin revealed a normal epidermis without keratinocyte death (cleaved caspase-3 staining in <xref ref-type="fig" rid="fig1">Figure 1C</xref>), skin inflammation (F4/80 staining in <xref ref-type="fig" rid="fig1">Figure 1C</xref>), or epidermal hyperplasia (H&amp;E, Keratin 6, Keratin 10, and Loricrin staining in <xref ref-type="fig" rid="fig1">Figure 1C</xref> and quantification in <xref ref-type="fig" rid="fig1">Figure 1D</xref>), similar to <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic> <sup><italic>−/−</italic></sup> animals (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>). These results demonstrate that TNFR1 signaling in epidermal keratinocytes is essential for the pathogenesis of skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice.<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.003</object-id><label>Figure 1.</label><caption><title>Tumor necrosis factor receptor 1 (TNFR1) signaling in keratinocytes triggers chronic proliferative dermatitis phenotype in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice.</title><p>(<bold>A</bold>) Flow cytometric analysis of TNFR1 expression on the isolated keratinocytes from mice with the indicated genotypes. (<bold>B</bold> and <bold>C</bold>) Macroscopic pictures, Hematoxylin and Eosin staining (H&amp;E), Keratin 6, 14, 10 and Loricrin as well as cleaved caspase-3 and F4/80 staining of the skin sections from 14-week-old littermate mice of the indicated genotypes. The scale bars are 100 μm. (<bold>D</bold>) Microscopic quantification of the epidermal thickness from 12–18-week-old mice of the indicated genotypes and their littermate controls (Ctr), which consisted of the following genotypes: <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;TNFR1<sup>E-KO</sup>, and <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;TNFR1<sup>E-KO</sup>. The <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> group consisted of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/wt</italic></sup> mice that were littermates of the <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice. The <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup> mice were derived from a different line and shown here is the picture and the staining from the age-matched mice. Bars represent mean values ± SEM. Statistical significance was determined using the Student's <italic>t</italic> test (***p ≤ 0.001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.003">http://dx.doi.org/10.7554/eLife.03422.003</ext-link></p></caption><graphic xlink:href="elife-03422-fig1-v1"/></fig></p></sec><sec id="s2-2"><title>Epidermal FADD-dependent TNFR1-induced death of keratinocytes induces skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice</title><p>Having established keratinocyte-intrinsic TNFR1 signaling as a key spatial event triggering skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, we sought to investigate the cell death mechanisms by which epithelial TNFR1 induces the inflammatory response. We and others have shown that increased numbers of keratinocytes in the epidermis of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice undergo apoptosis, as indicated by the presence of cleaved caspase-3 (<xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>; <xref ref-type="bibr" rid="bib17">Liang and Sundberg, 2011</xref>) (also see <xref ref-type="fig" rid="fig1">Figure 1C</xref>). In addition, it was suggested that Sharpin deficiency sensitizes primary keratinocytes to both TNF-induced caspase-dependent apoptosis and RIP-kinase-dependent necroptosis (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>). We therefore used genetic mouse models to address the role of FADD/caspase-8-dependent apoptosis and RIPK3-dependent necroptosis in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. To address the role of RIPK3-dependent necroptosis, we generated mice lacking both Sharpin and RIPK3 by crossing <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> with <italic>Ripk3</italic><sup>−/−</sup> animals (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Double deficient <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup>−/−</sup> mice developed skin lesions similar to those of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, demonstrating that RIPK3 deficiency did not prevent the development of skin inflammation (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). However, the initiation of the skin phenotype was delayed in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup>−/−</sup> animals, which started to show lesions after the age of 10 weeks but showed a large variability in onset and severity with some mice showing only mild lesions even at the age of 19 weeks (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice also showed variability with lesion onset between 8 and 11 weeks, but all mice showed severe lesions by the age of 12–14 weeks. Quantification of epidermal thickness revealed that RIPK3 deficiency mildly ameliorated the severity of skin lesions (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These results showed that, although RIPK3-dependent necroptosis contributes to accelerating the onset and exacerbating the severity of the phenotype, it is not essential for the pathogenesis of the inflammatory skin lesions in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.004</object-id><label>Figure 2.</label><caption><title>Fas-associated protein with death domain (FADD) deficiency in keratinocytes prevents skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice.</title><p>(<bold>A</bold> and <bold>B</bold>) Macroscopic pictures, Hematoxylin and Eosin staining (H&amp;E), Keratin 6, 14, 10 and Loricrin as well as cleaved caspase-3 and F4/80 staining of skin sections from 14-week-old mice of the indicated genotypes. The scale bars are 100 μm. (<bold>C</bold>) Microscopic quantification of the epidermal thickness from 12–18-week-old mice of the indicated genotypes and their littermate controls (Ctr), which consisted of the following genotypes: <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>. The <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> group consisted of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/wt</italic></sup> mice that were littermates of the <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice. <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice were derived from the same breeding line as <italic>Sharpin</italic><sup><italic>cpdmcpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice and consisted of the genotype <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>. Bars represent mean values ± SEM. Statistical significance was determined using the Student's <italic>t</italic> test (***p ≤ 0.001, **p ≤ 0.01).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.004">http://dx.doi.org/10.7554/eLife.03422.004</ext-link></p></caption><graphic xlink:href="elife-03422-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03422.005</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Variability among <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice at a similar age.</title><p>The gross appearance of severe skin lesions in two <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice at the age of 19 weeks (left) and a <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mouse at the same age with only a very mild phenotype (right).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.005">http://dx.doi.org/10.7554/eLife.03422.005</ext-link></p></caption><graphic xlink:href="elife-03422-fig2-figsupp1-v1"/></fig></fig-group></p><p>Next, we sought to address whether FADD/caspase-8-dependent apoptosis of Sharpin-deficient keratinocytes induces TNF-dependent skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. Since deficiency of caspase-8 or FADD alone in epidermal keratinocytes triggers a RIPK3-dependent skin inflammation (<xref ref-type="bibr" rid="bib1">Bonnet et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Weinlich et al., 2013</xref>), we could not directly investigate the role of FADD or caspase-8 in the TNF-induced death of Sharpin-deficient keratinocytes in vivo. However, taking advantage of the fact that concomitant deletion of RIPK3 fully prevents skin lesion formation in mice with keratinocyte-restricted FADD knockout (FADD<sup>E-KO</sup>) (<xref ref-type="bibr" rid="bib1">Bonnet et al., 2011</xref>), we generated <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup>−/−</sup> mice that also lacked FADD specifically in keratinocytes (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice did not develop any macroscopic (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) or histological (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) skin lesions up to the age of 4 months, as they showed normal keratinocyte proliferation and differentiation without any signs of inflammation or epidermal hyperplasia (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). Moreover, apoptosis of keratinocytes observed in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice was completely prevented in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice, as shown by the absence of cleaved caspase-3 positive cells (compare <xref ref-type="fig" rid="fig2">Figure 2B</xref> with <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Taken together, these results showed that combined inhibition of FADD/caspase-8-dependent apoptosis and RIPK3-dependent necroptosis prevented keratinocyte death and the development of skin lesions in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, providing in vivo genetic evidence that skin inflammation is triggered by TNFR1-induced death of Sharpin-deficient keratinocytes.</p></sec><sec id="s2-3"><title>TRADD-dependent apoptosis of Sharpin-deficient keratinocytes triggers skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice</title><p>Our findings strongly suggest that FADD-dependent apoptosis of Sharpin-deficient keratinocytes triggers skin inflammation. However, since the role of FADD can only be addressed in a RIPK3-deficient background, it remains possible that FADD-dependent apoptosis and RIPK3-dependent necroptosis might share a redundant function in inducing the cell death of Sharpin-deficient keratinocytes and triggering skin inflammation. To directly address the role of TNFR1-induced apoptosis in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, we employed mice carrying conditional alleles for TRADD, an adapter molecule that is important for the induction of inflammatory and apoptotic signaling downstream of TNFR1 (<xref ref-type="bibr" rid="bib3">Chen et al., 2008</xref>; <xref ref-type="bibr" rid="bib19">Michallet et al., 2008</xref>). It has been shown that TRADD deficiency partially inhibits TNFR1-induced activation of NF-κB and MAP kinase pathways and fully prevents TNFR1-induced apoptosis in mouse embryonic fibroblasts (MEFs) in vitro and in hepatocytes in vivo (<xref ref-type="bibr" rid="bib4">Ermolaeva et al., 2008</xref>). To examine the role of TRADD in TNFR1-induced apoptosis and necroptosis, we analyzed the response of wild type and TRADD-deficient primary MEFs to TNF stimulation in the presence of cycloheximide (CHX), caspase inhibitor (Z-VAD-FMK), and RIPK1 inhibitor (Necrostatin-1) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). As expected, TRADD-deficient MEFs were resistant to apoptosis induced by TNF and CHX. However, in contrast to earlier studies (<xref ref-type="bibr" rid="bib26">Pobezinskaya et al., 2008</xref>), we found that TRADD-deficient MEFs were sensitive to necroptosis induced by TNF, CHX, and Z-VAD-FMK. These results demonstrated that TRADD deficiency specifically blocks TNFR1-induced apoptosis (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We therefore generated <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice lacking TRADD specifically in keratinocytes by crossing <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> with <italic>K14Cre-Tradd</italic><sup><italic>fl/fl</italic></sup> mice (<italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TRADD<sup>E-KO</sup>) (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Indeed, keratinocyte-restricted TRADD deficiency prevented skin lesion development in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, as shown by macroscopic and histological analysis (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Collectively, our results show that TNFR1-induced TRADD- and FADD-dependent apoptosis of Sharpin-deficient keratinocytes triggers the chronic proliferative dermatitis phenotype in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.006</object-id><label>Figure 3.</label><caption><title>Tumor necrosis factor receptor 1-associated death domain (TRADD) deficiency in keratinocytes prevents skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice.</title><p>(<bold>A</bold>) The percentage viability of wild type (WT) mouse embryonic fibroblasts (MEFs) (n = 3) and TRADD-deficient MEFs (n = 3) upon tumor necrosis factor (TNF), cycloheximide (CHX), caspase inhibitor (zVAD), and Necrostatin-1 (Nec) treatment alone or in combination for 20 hr and measurement by WST-1 assay. Bars represent average cell viability (± SD) of three independent experiments. (<bold>B</bold> and <bold>C</bold>) Macroscopic gross appearance of the WT (+/+) and littermate mice of the indicated genotype at the age of 12 weeks (<bold>B</bold>) and (H&amp;E), Keratin 6, 14, 10 and Loricrin as well as cleaved caspase-3 and F4/80 staining of the skin sections from 12-week-old mice of the indicated genotypes (<bold>C</bold>). Scale bars in (<bold>C</bold>) are 100 μm. (<bold>D</bold>) Microscopic quantification of the epidermal thickness from 12-week-old littermate mice of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;TRADD<sup>E-KO</sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TRADD<sup>E-KO</sup> and age-matched WT (+/+) is shown. Bars represent mean values ± SD. Statistical significance was determined using the one-way ANOVA test (****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.006">http://dx.doi.org/10.7554/eLife.03422.006</ext-link></p></caption><graphic xlink:href="elife-03422-fig3-v1"/></fig></p></sec><sec id="s2-4"><title>TNFR1-induced signaling in non-epidermal cells induces extracutaneous organ inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice</title><p>In addition to dermatitis, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice develop splenomegaly and inflammation in other organs such as liver and lung (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). We found that systemic deficiency of TNFR1 prevented the development of liver inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), consistent with earlier results showing that TNF deficiency also inhibited liver inflammation in these animals (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>). We also found that TNFR1 deficiency prevented lung inflammation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and the development of splenomegaly (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. TNFR1 deficiency also corrected the splenic structure defects in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), in contrast to the report by <xref ref-type="bibr" rid="bib5">Gerlach et al. (2011)</xref> that TNF deficiency could not rescue the splenic structural abnormalities of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. This contradiction likely stems from the fact that Gerlach et al. compared the spleens of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice with wild type mice. However, considering that TNFR1- and TNF-deficient animals have altered splenic structures characterized by lack of B cell lymphoid follicles and marginal zone abnormalities (<xref ref-type="bibr" rid="bib21">Pasparakis et al., 1996a</xref>, <xref ref-type="bibr" rid="bib22">1996b</xref>, <xref ref-type="bibr" rid="bib24">2000</xref>), TNFR1 or TNF deficiency cannot restore the spleen structure of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice to that of a wild type mouse. Keratinocyte-restricted TNFR1 deficiency could not rescue the extracutaneous pathologies in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, suggesting that these develop independently from the skin lesions (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). These results demonstrate that TNFR1 signaling in non-epidermal cells triggers splenomegaly and extracutaneous inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. We also analyzed the liver, lung, and spleen of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice. Interestingly, we observed partial normalization of liver and lung inflammation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), splenomegaly and the splenic structure in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>), suggesting that RIPK3-mediated necroptosis contributes to the extracutaneous inflammatory pathologies. <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice showed very similar histology of the liver, lung, and spleen to <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice, indicating that the extracutaneous phenotype in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice is mainly attributed to RIPK3 signaling and not to epidermal FADD signaling (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In addition, we performed cleaved caspase-3 staining and TUNEL staining on liver, lung, and spleen tissue sections obtained from <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup>, and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice and from their respective controls <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup>, and <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice (n = 2–4 mice from each genotype) (<xref ref-type="fig" rid="fig5s1 fig5s2 fig5s3">Figure 5—figure supplements 1–3</xref>). We observed increased active caspase-3 and TUNEL positive cells in the lung and liver of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice compared with <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup> mice, whereas the spleen did not seem to have an increased number of cleaved caspase-3 positive cells compared with the control mice. The numbers of cleaved caspase-3 positive and TUNEL positive cells were reduced in <italic>Sharpin</italic><sup><italic>cpdm/</italic>cpdm</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup> mice, whereas <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice showed similar cleaved caspase-3 and TUNEL positive cells to <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. These findings essentially showed that, in the mice showing no or less inflammation, the numbers of both cleaved caspase-3 and TUNEL positive cells were reduced. Furthermore, we observed that liver and lung inflammation as well as splenomegaly and the defect of splenic structure were not altered by keratinocyte-specific depletion of TRADD in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>), providing further support for the notion that the development of extracutaneous organ inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice occurs independently from the skin lesions.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.007</object-id><label>Figure 4.</label><caption><title>Tumor necrosis factor receptor 1 (TNFR1) deficiency in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice rescues the inflammation of lung, liver and splenomegaly but not epidermal keratinocyte-restricted knockout of TNFR1.</title><p>(<bold>A</bold> and <bold>B</bold>) H&amp;E staining of liver, lung and spleen, and macroscopic pictures of spleen from mice with the indicated genotypes as well as measurement of spleen weight from 12–18-week-old <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice and their littermate controls (Ctr), which consisted of the following genotypes: <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;TNFR1<sup>E-KO</sup>, and <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;TNFR1<sup>E-KO</sup>. The <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> group consisted of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/wt</italic></sup> mice that were littermates of the <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice. Scale bars in (<bold>A</bold>) are 100 μm. Results are expressed as mean values ± SEM. Statistical significance was determined using unpaired Student's <italic>t</italic> test (two-tailed) (***p ≤ 0.001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.007">http://dx.doi.org/10.7554/eLife.03422.007</ext-link></p></caption><graphic xlink:href="elife-03422-fig4-v1"/></fig><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.008</object-id><label>Figure 5.</label><caption><title>Receptor-interacting protein kinase 3 (<italic>Ripk3</italic><sup>−/−</sup>) and epidermis-specific Fas-associated protein with death domain (FADD) together with <italic>Ripk3</italic><sup>−/− </sup>(FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic><sup>−/−</sup></italic></sup>) in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice partially rescues the inflammation of the lung, liver, and splenomegaly.</title><p>(<bold>A</bold> and <bold>B</bold>) H&amp;E staining of liver, lung and spleen, and macroscopic pictures of spleen from mice with the indicated genotypes as well as measurement of spleen weight from 12–18-week-old <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice and their littermate controls (Ctr), which consisted of the following genotypes: <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, and <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>. The <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> group consisted of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/fl</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Tnfrsf1a</italic><sup><italic>fl/wt</italic></sup> mice that were littermates of the <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup> mice. The <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice were derived from the same breeding line as <italic>Sharpin</italic><sup><italic>cpdmcpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice and consisted of the genotype <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>. Scale bars in (<bold>A</bold>) are 100 μm. Results are expressed as mean values ± SEM. Statistical significance was determined using unpaired Student's <italic>t</italic> test (two-tailed) (***p ≤ 0.001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.008">http://dx.doi.org/10.7554/eLife.03422.008</ext-link></p></caption><graphic xlink:href="elife-03422-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03422.009</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Cell death in the spleen of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>; <italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice.</title><p>(<bold>A</bold> and <bold>B</bold>) Cleaved caspase-3 (<bold>A</bold>) and TUNEL (<bold>B</bold>) staining on the spleen tissue sections from mice with the indicated genotypes between 12–18 weeks. The control mice compared were from the same breeding but not always littermates. Representative images are shown. The scale bars are 100 μm. Nuclei in (<bold>B</bold>) were visualized using DAPI.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.009">http://dx.doi.org/10.7554/eLife.03422.009</ext-link></p></caption><graphic xlink:href="elife-03422-fig5-figsupp1-v1"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03422.010</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Cell death in the liver of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>; <italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice.</title><p>(<bold>A</bold> and <bold>B</bold>) Cleaved caspase-3 (<bold>A</bold>) and TUNEL (<bold>B</bold>) staining of liver tissue sections from mice with the indicated genotypes between 12–18 weeks. The control mice compared were from the same breeding but not always littermates. Representative images are shown. The scale bars are 100 μm. Nuclei in (<bold>B</bold>) were visualized using DAPI.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.010">http://dx.doi.org/10.7554/eLife.03422.010</ext-link></p></caption><graphic xlink:href="elife-03422-fig5-figsupp2-v1"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03422.011</object-id><label>Figure 5—figure supplement 3.</label><caption><title>Cell death in the lung of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>; <italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> mice.</title><p>(<bold>A</bold> and <bold>B</bold>) Cleaved caspase-3 (<bold>A</bold>) and TUNEL (<bold>B</bold>) staining of lung tissue sections from mice with the indicated genotypes between 12–18 weeks. The control mice compared were from the same breeding but not always littermates. Representative images are shown. The scale bars are 100 μm. Nuclei in (<bold>B</bold>) were visualized using DAPI.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.011">http://dx.doi.org/10.7554/eLife.03422.011</ext-link></p></caption><graphic xlink:href="elife-03422-fig5-figsupp3-v1"/></fig></fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.012</object-id><label>Figure 6.</label><caption><title>Epidermal keratinocyte-restricted knockout of tumor necrosis factor receptor 1-associated death domain (TRADD) (TRADD<sup>E-KO</sup>) in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice has a minor effect on the inflammation of the lung, liver, and splenomegaly.</title><p>(<bold>A</bold> and <bold>B</bold>) H&amp;E staining of liver, lung, and spleen and macroscopic pictures of spleen as well as measurement of spleen weight from mice with the indicated genotypes derived from wild type (+/+), <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, TRADD<sup>E-KO</sup> or <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TRADD<sup>E-KO</sup> mice at the age of 12 weeks. The mice used here are the littermates. Scale bars in (<bold>A</bold>) are 100 μm. Results are expressed as mean values ± SD. Statistical significance was determined using ANOVA test (***p ≤ 0.001 and ****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.012">http://dx.doi.org/10.7554/eLife.03422.012</ext-link></p></caption><graphic xlink:href="elife-03422-fig6-v1"/></fig></p></sec><sec id="s2-5"><title>Sharpin regulates TNF-induced apoptosis</title><p>Our in vivo genetic experiments showed that TNFR1-induced apoptosis of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> keratinocytes causes skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. We therefore investigated the molecular mechanisms by which Sharpin prevents TNFR1-induced apoptosis. We first examined the induction of apoptosis in MEFs derived from <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice stimulated with TNF alone or TNF + CHX using various assays. We observed increased sensitivity to TNF + CHX-induced apoptosis in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs compared with wild type MEFs, as determined by immunocytochemical detection of cleaved caspase-3 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), detection of annexin V positive cells by fluorescence-activated cell sorting (FACS) analysis (<xref ref-type="fig" rid="fig7">Figure 7B</xref>), analysis of the cleavage of caspase-3 and Poly (ADP-ribose) polymerase (PARP) by immunoblotting (<xref ref-type="fig" rid="fig7">Figure 7C</xref>) (<xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>), and luminescent-based caspase-8 activity assay (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs also showed increased cleavage of caspase-3 and PARP (<xref ref-type="fig" rid="fig7">Figure 7E</xref>) and caspase-8 activity (<xref ref-type="fig" rid="fig7">Figure 7F</xref>) in response to stimulation with TNF alone although, in the absence of CHX, the response was considerably weaker. To further analyze the cellular functions of Sharpin in anti-apoptotic signaling, we used a human keratinocyte cell line, HaCaT cells (<xref ref-type="bibr" rid="bib2">Boukamp et al., 1988</xref>). By using lentiviral-based shRNA knockdown, Sharpin was stably depleted in HaCaT cells (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Sharpin-deficient HaCaT and control shRNA-introduced HaCaT cells were treated with TNF alone or TNF + CHX, and the induction of apoptosis was assessed by FACS analysis of annexin V positive cells (<xref ref-type="fig" rid="fig8">Figure 8B</xref>) and measurement of caspase-8 activity (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). Similar to <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs, Sharpin knockdown sensitized HaCaT cells to apoptosis induced by TNF or TNF + CHX. Interestingly, treatment with Necrostatin-1, a RIPK1 inhibitor, suppressed caspase-8 activation in Sharpin-deficient HaCaT cells (<xref ref-type="fig" rid="fig8">Figure 8D</xref>), suggesting an involvement of RIPK1 in the induction of TNF-induced death of Sharpin-deficient keratinocytes as suggested recently by Berger et al. (<xref ref-type="bibr" rid="bib1a">Berger et al., 2014</xref>). Our results collectively suggest that Sharpin plays a critical role in protecting against TNF-induced apoptosis. To distinguish between the possibilities that the anti-apoptotic protection afforded by Sharpin is a LUBAC-independent function of Sharpin, we assessed the involvement of the catalytic LUBAC component HOIP in the regulation of apoptosis. HOIP expression was stably knocked down in HaCaT cells using shRNA (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>), and the cells were examined for apoptosis induced by TNF alone or TNF + CHX using FACS analysis (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>) and a caspase-8 activity assay (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C and D</xref>). As expected and consistent with a LUBAC-dependent Sharpin function, HOIP deficiency sensitized HaCaT cells to apoptosis induced by TNF alone or by TNF + CHX, akin to that observed in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs or Sharpin-deficient HaCaT cells. There results provide strong support that a LUBAC-dependent Sharpin function plays a role in the regulation of apoptosis in keratinocytes.<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.013</object-id><label>Figure 7.</label><caption><title>Sharpin regulates tumor necrosis factor (TNF)-induced apoptosis signaling cascade in mouse embryonic fibroblasts (MEFs).</title><p>(<bold>A</bold>–<bold>D</bold>) TNF- and cycloheximide (CHX)-induced apoptosis in wild type (+/+) or <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs. Apoptosis in MEFs stimulated with TNF (10 ng/ml) and CHX (1 μg/ml) for 4 hr was examined by immunofluorescent staining using α-cleaved caspase-3 antibody with Alexa488 conjugated secondary antibody (<bold>A</bold>), by fluorescence-activated cell sorting (FACS) analysis using annexin V staining (<bold>B</bold>), by immunoblotting using α-cleaved caspase-3 and α-Poly (ADP-ribose) polymerase (PARP) antibodies (<bold>C</bold>), or by caspase-8 activity assay measured using a luminol-based assay. Scale bars in (<bold>A</bold>) are 100 μm. (<bold>E</bold> and <bold>F</bold>) TNF-induced apoptosis in MEFs analyzed by immunoblotting (<bold>E</bold>) or by caspase-8 activity assay (<bold>F</bold>) as in (<bold>C</bold> and <bold>D</bold>). Results are expressed as mean values ± SD. Statistical significance was determined using ANOVA test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.013">http://dx.doi.org/10.7554/eLife.03422.013</ext-link></p></caption><graphic xlink:href="elife-03422-fig7-v1"/></fig><fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.014</object-id><label>Figure 8.</label><caption><title>Sharpin regulates tumor necrosis factor (TNF)-induced apoptosis signaling cascade in HaCaT cells.</title><p>(<bold>A</bold>) Immunoblotting of stable knockdown Sharpin in HaCaT cells using α-Sharpin antibody. Control shRNA (Ctr) was used for the control knockdown. α-Vinculin antibody was used for the loading control. (<bold>B</bold>) Fluorescence-activated cell sorting (FACS) analysis of annexin V staining in parental, Ctr, and Sharpin knockdown HaCaT cells, stimulated with TNF (100 ng/ml) for 16 hr or TNF with cycloheximide (CHX) (1 μg/ml) for 6 hr. (<bold>C</bold>) Caspase-8 activity measurement using a luminol-based assay upon stimulation with TNF alone, or TNF and CHX for the indicated time in Ctr and Sharpin knockdown HaCaT cells. (<bold>D</bold>) Caspase-8 activity measurement upon stimulation with TNF, TNF + CHX with or without Necrostatin-1 (Nec) (30 μmol) for 6 hr in Ctr and Sharpin knockdown HaCaT cells. Results are expressed as mean values ± SD. Statistical significance was determined using ANOVA test (****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.014">http://dx.doi.org/10.7554/eLife.03422.014</ext-link></p></caption><graphic xlink:href="elife-03422-fig8-v1"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03422.015</object-id><label>Figure 8—figure supplement 1.</label><caption><title>A LUBAC component, HOIL-1L interacting protein (HOIP), plays a role in tumor necrosis factor (TNF)-induced apoptosis in HaCaT cells.</title><p>(<bold>A</bold>–<bold>D</bold>) Immunoblot of HOIP (<bold>A</bold>) after stable knocked down of HOIP in HaCaT cells by shRNA. α-Tubulin antibody was used for the loading control. Fluorescence-activated cell sorting (FACS) analysis of annexin V positive cells after stimulation of control (Ctr) and HOIP knockdown HaCaT cells with TNF alone or TNF + cycloheximide (CHX) (<bold>B</bold>) and caspase-8 activity assay (<bold>B</bold> and <bold>D</bold>) after stimulation of Ctr and HOIP knockdown HaCaT cells with TNF alone (<bold>C</bold>) or TNF + CHX (<bold>D</bold>). Results are expressed as mean values ± SD. Statistical significance was determined using ANOVA test (**p ≤ 0.01, ****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.015">http://dx.doi.org/10.7554/eLife.03422.015</ext-link></p></caption><graphic xlink:href="elife-03422-fig8-figsupp1-v1"/></fig></fig-group></p></sec><sec id="s2-6"><title>FADD and TRADD have a major role in Sharpin-regulated TNF-induced apoptosis</title><p>As keratinocyte apoptosis and skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice were suppressed by epidermal-specific deletion of FADD or TRADD, we sought to investigate how the lack of FADD, TRADD, and RIPK3 proteins impact on TNF-induced cell viability in Sharpin-deficient cells. To address this, primary keratinocytes were isolated from newborn pups, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, and their control littermates, <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup> or <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup> <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, respectively. Cells were treated with increasing concentrations of TNF alone or TNF + CHX for 24 hr and their viability was analyzed using the WST-1 assay (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). Although TNF + CHX treatment strongly induced the death of Sharpin-deficient keratinocytes, TNF treatment alone had a very small effect in reducing the viability of Sharpin-deficient keratinocytes by about 10% compared with controls. Interestingly, the combined lack of FADD and RIPK3 in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup>−/−</sup> keratinocytes fully rescued the increased sensitivity of Sharpin-deficient keratinocytes to TNF + CHX (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). However, keratinocytes obtained from <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup>−/−</sup> showed a similar response to TNF + CHX as <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> keratinocytes, demonstrating that RIPK3 deficiency does not prevent the death of Sharpin-deficient keratinocytes. Therefore, Sharpin deficiency primarily sensitizes keratinocytes to FADD-mediated apoptosis and not to RIPK3-mediated necroptosis. To further examine a direct role of FADD in Sharpin-deficient cells without involvement of RIPK3, we generated HaCaT cells in which Sharpin and FADD were both stably knocked down by shRNA (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). Upon treatment with TNF alone or TNF + CHX, HaCaT cells lacking both Sharpin and FADD showed reduced caspase-8 activity compared with Sharpin-deficient HaCaT cells (<xref ref-type="fig" rid="fig9">Figure 9C,D</xref>). Similar to the keratinocytes, we generated FADD-deficient <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs and analyzed the effect of FADD deficiency on apoptosis induced by TNF alone and by TNF + CHX in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>) and observed that FADD deficiency significantly suppressed the annexin V positive cells and caspase-8 activity in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B and C</xref>). To address an involvement of TRADD in TNF-induced sensitivity of Sharpin-deficient HaCaT cells, we used HaCaT cells which were knockdown for Sharpin and TRADD expression. In comparison to caspase-8 activity induced by TNF alone or TNF + CHX in Sharpin-deficient HaCaT cells, TRADD deficiency significantly suppressed caspase-8 activation (<xref ref-type="fig" rid="fig9">Figure 9E–G</xref>). These data collectively suggest that regulation of Sharpin-dependent anti-apoptosis signaling depends on FADD and TRADD in a cell-intrinsic manner.<fig-group><fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.03422.016</object-id><label>Figure 9.</label><caption><title>Fas-associated protein with death domain (FADD)- and tumor necrosis factor receptor 1-associated death domain (TRADD)-dependent enhanced sensitivity of Sharpin-deficient keratinocytes to tumor necrosis factor (TNF)-induced apoptosis.</title><p>(<bold>A</bold>) Percentage viability of primary keratinocytes isolated from <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup>, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup><italic>−/−</italic></sup> and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;TNFR1<sup>E-KO</sup>, and their respective control pups (n = 2) upon treatment with increasing TNF concentration (20, 50 and 100 ng/ml) in the presence or absence of cycloheximide (CHX) (1 μg/ml) for 24 hr. Viability of TNF-treated cells was normalized over their untreated control cells, and viability of TNF + CHX-treated cells was normalized over their CHX-treated control cells. The result shown here is representative of two independent experiments. The percentage viability was assessed using the WST-1 assay. Bars represent mean values ± SEM. Statistical significance was determined using the Student's <italic>t</italic> test (**p ≤ 0.01, *p ≤ 0.05). (<bold>B</bold>–<bold>G</bold>) Sharpin with FADD (<bold>B</bold>) or TRADD (<bold>E</bold>) was stably knocked down in HaCaT cells. Knockdown efficiency was analyzed by immunoblotting using α-Sharpin, α-FADD, and α-TRADD antibodies. Caspase-8 activity measurement in Sharpin knockdown, FADD knockdown, and double knockdown of Sharpin and FADD HaCaT cells (<bold>C</bold> and <bold>D</bold>) as well as Sharpin knockdown, TRADD knockdown, and double knockdown of Sharpin and TRADD HaCaT cells (<bold>F</bold> and <bold>G</bold>) upon treatment with TNF alone (<bold>C</bold> and <bold>F</bold>) or TNF + CHX (<bold>D</bold> and <bold>G</bold>) for the indicated time. Results are expressed as mean values ± SD. Statistical significance was determined using ANOVA test (****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.016">http://dx.doi.org/10.7554/eLife.03422.016</ext-link></p></caption><graphic xlink:href="elife-03422-fig9-v1"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03422.017</object-id><label>Figure 9—figure supplement 1.</label><caption><title>Fas-associated protein with death domain (FADD) plays an important role in the Sharpin-dependent apoptosis signaling.</title><p>(<bold>A</bold>) Immunoblot of FADD after stable knocked down of FADD in wild type (+/+) mouse embryonic fibroblasts (MEFs) and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs by shRNA. α-Vinculin antibody was used for the loading control. (<bold>B</bold>) Fluorescence-activated cell sorting (FACS) analysis of annexin V positive cells after stimulation with tumor necrosis factor (TNF) + cycloheximide (CHX) for 4 hr in +/+ shCtr MEFs, +/+ shFADD MEFs, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> shCtr MEFs, and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> shFADD MEFs. (<bold>C</bold>) Caspase-8 activity measurement upon stimulation with TNF with or without CHX for the indicated time in +/+ shCtr MEFs, +/+ shFADD MEFs, <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> shCtr MEFs and <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> shFADD MEFs. Results are expressed as mean values ± SD. Statistical significance was determined using ANOVA test (****p ≤ 0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03422.017">http://dx.doi.org/10.7554/eLife.03422.017</ext-link></p></caption><graphic xlink:href="elife-03422-fig9-figsupp1-v1"/></fig></fig-group></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Ubiquitination regulates a wide variety of biological functions by generating ubiquitin chains with different linkages on substrates (<xref ref-type="bibr" rid="bib9">Ikeda and Dikic, 2008</xref>; <xref ref-type="bibr" rid="bib13">Komander and Rape, 2012</xref>). One of the atypical linkage types is the Met-1/linearly-linked ubiquitin chain which is specifically generated by the LUBAC E3 ligase complex (<xref ref-type="bibr" rid="bib12">Kirisako et al., 2006</xref>). Sharpin is a critical component of the LUBAC complex (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Tokunaga et al., 2011</xref>) and its deficiency in mice leads to severe TNF-dependent inflammation in multiple organs including the skin (<xref ref-type="bibr" rid="bib29">Seymour et al., 2007</xref>), suggesting that Sharpin has an important role in preventing inflammation. However, the mechanisms by which Sharpin prevents TNF-mediated inflammation in the skin and other organs have remained elusive.</p><p>We show here that TNFR1 signaling in keratinocytes is essential for the pathogenesis of skin inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice. In addition, we provide genetic evidence that TNFR1-mediated, TRADD- and FADD-dependent apoptosis of Sharpin-deficient keratinocytes induces skin inflammation in these mice. RIPK3 deficiency only mildly delayed and ameliorated the severity of skin lesions in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice, showing that RIPK3-dependent necroptosis plays a minor role in driving skin inflammation in this model, which was also shown by Rickard et al. (<xref ref-type="bibr" rid="bib26a">Rickard et al., 2014</xref>). These results demonstrate that Sharpin deficiency triggers skin inflammation by sensitizing keratinocytes to TNF-induced apoptosis. Furthermore, we found that inflammation in other organs including lung and liver as well as splenomegaly and altered splenic structure observed in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice also depend on TNFR1 signaling and occur independently of the skin lesions. Together, these findings identified a cell-intrinsic function of Sharpin in inhibiting TNFR1-induced apoptosis that is essential for the maintenance of tissue homeostasis and the prevention of multi-organ inflammation.</p><p>In this study we have shown that Sharpin and HOIP, components of LUBAC, negatively regulate apoptotic pathways in keratinocytes. Our data suggest that Sharpin and HOIP act in an active ligase complex and raise the intriguing possibility that linear ubiquitination of an unknown target(s) inhibits TNF-induced apoptosis in keratinocytes. Ubiquitin signals have been implicated in the regulation of the death-inducing signaling complex (DISC). For example, cullin 3-based ubiquitination of caspase-8 by both Lys48- and Lys63-linked polyubiquitin chains brings caspase-8 into p62-containing aggregates leading to its activation and to commitment to apoptotic cell death (<xref ref-type="bibr" rid="bib10">Jin et al., 2009</xref>). Furthermore, it was shown that FADD ubiquitination induced by Makorin Ring Finger Protein 1 (MKRN1) E3 ligase leads to the proteasome-dependent degradation of FADD, and MKRN1 depletion in breast cancer cells accelerates TNF-related apoptosis-inducing ligand (TRAIL)-induced DISC formation and apoptosis (<xref ref-type="bibr" rid="bib16">Lee et al., 2012</xref>). Since we did not detect significant changes in total FADD protein levels in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> MEFs in comparison to the wild type cells (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>), it suggests that protein stability is not controlled by Sharpin. It is also important to elucidate spatial and temporal regulation of DISC and TNFR complex II component ubiquitination and to identify the E3 ligases that mediate these ubiquitinations for the better understanding of biological functions of TNF signaling. Lastly, our study sheds new light on the specific functions of Sharpin as an integral component of the LUBAC E3 ligase complex. For example, both HOIL-1L and Sharpin are expressed in keratinocytes and have redundant roles in activating the NF-κB signaling pathway in MEFs (<xref ref-type="bibr" rid="bib7">Haas et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>). Yet, Sharpin-deficient mice develop inflammation in the skin whereas HOIL-1L knockout mice showed no obvious dermatitis phenotypes (<xref ref-type="bibr" rid="bib33">Tokunaga et al., 2009</xref>). Interestingly, previous studies have shown that the analysis of complex formation of Sharpin, HOIL-1L, and HOIP suggested that some populations of Sharpin and HOIL-1L may exist in different molecular complexes from HOIP (<xref ref-type="bibr" rid="bib5">Gerlach et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Tokunaga et al., 2011</xref>). This raises the question whether Sharpin and HOIL-1L could individually regulate biological functions depending on the cell types, tissues, and pathogenic conditions. Precise examination of the effects of tissue-specific depletion of the LUBAC components in mice is needed to better understand the functional roles of each of the LUBAC components in vivo. Here we report the specific function of Sharpin in the regulation of apoptosis and skin inflammation, which are mediated through FADD and TRADD. Together, further studies of the regulatory mechanisms controlling inflammation in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> mice will be important for the better understanding of the unique functions of Sharpin in vivo.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>The following mouse lines were used: <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> C57BL/KaLawRij (<xref ref-type="bibr" rid="bib29">Seymour et al., 2007</xref>; <xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>), <italic>Tradd</italic><sup>fl/fl</sup>, <italic>Fadd</italic><sup><italic>fl/fl</italic></sup> (<xref ref-type="bibr" rid="bib18">Mc Guire et al., 2010</xref>), <italic>K14-Cre</italic> (<xref ref-type="bibr" rid="bib23">Pasparakis et al., 2002</xref>), <italic>Tnfrsf1a</italic><sup><italic>−/−</italic></sup> (<xref ref-type="bibr" rid="bib25">Pfeffer et al., 1993</xref>), <italic>Tnfrsf1a</italic><sup>fl/fl</sup> (<xref ref-type="bibr" rid="bib35">Van Hauwermeiren et al., 2013</xref>), and <italic>Ripk3</italic><sup><italic>−/−</italic></sup> (<xref ref-type="bibr" rid="bib20">Newton et al., 2004</xref>). All animal procedures were conducted in accordance with European, national, and institutional guidelines and protocols and were approved by local government authorities.</p></sec><sec id="s4-2"><title>Plasmids, antibodies and cells</title><p>pLKO.1-shRNA-control (AACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTT), pLKO.1-shRNA-mouse FADD (CCACACTTGGAGCCCAATAAACTCGAGTTTATTGGGCTCCAAGTGTGG), pLKO.1-shRNA-human HOIP (TGCTCCTTTGGCTTCATATATCTCGAGATATATGAAGCCAAAGGAGCA), pLKO.1-shRNA-human Sharpin (GTGTTCTCAGAGCTCGGTTTCCTCGAGGAAACCGAGCTCTGAGAACAC), pLKO.1-shRNA-human FADD (CATGGAACTCAGACGCATCTACTCGAGTAGATGCGTCTGAGTTCCATG), and pLKO.1-shRNA-human TRADD (CTGAAACTCCACTTGGCCTATCTCGAGATAGGCCAAGTGGAGTTTCAG) were generated by a standard subcloning method. The following antibodies were purchased and used according to the manufacturers’ recommendations: anti-cleaved caspase-3 antibody (Asp175) (clone 5A1E; Cell Signaling Technology, Danvers, MA), anti-Vinculin antibody (Sigma, St Louis, MO), anti-PARP antibody (#9542; Cell Signaling Technology), anti-FADD antibody (clone 1F7; ENZO Life Sciences, Farmingdale, NY), anti-HOIP antibody (Aviva Systems Biology, San Diego, CA), anti-TRADD antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-Sharpin antibody has been described previously (<xref ref-type="bibr" rid="bib33">Tokunaga et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>).</p><p>Human Embryonic Kidney (HEK) 293T cells (ATCC, Boulevard Manassas, VA), immortalized mouse embryonic fibroblasts (MEFs), and HaCaT cells (a kind gift from Máté Borsos) were maintained at 37°C in 5% CO<sub>2</sub> condition in DMEM (Sigma) supplemented with 10% fetal calf serum (Life Technologies, Carlsbad, CA) and 100 U/ml penicillin and streptomycin (Invitrogen, Carlsbad, CA). Murine TNF was purchased from PeproTech (#315-01A, Rocky Hill, NJ).</p></sec><sec id="s4-3"><title>Immunohistochemistry and flow cytometry</title><p>Tissue samples from 12–18-week-old mice were fixed in 3.8–10% buffered formalin (skin) or 4% PFA (liver, lung and spleen) and subjected to histological analysis by H&amp;E staining, TUNEL or immunohistochemical analysis. Slides were scanned using Mirax Slide Scanner (Carl Zeiss, Germany). The following antibodies were used: K14, K6, K10 and Loricrin (Covance, Prinston, NJ), F4/80 (clone A3-1, AbD Serotec, homemade), active caspase-3 (Cell Signaling Technologies), and TRADD (H-278, Santa Cruz). Secondary antibodies were coupled to Biotin (Dako, Germany); signal was amplified by avidin-biotin-HRP detection system (ABC VectorLab Elite Kit, Burlingame, CA) and detected by peroxidase substrate (VectorLab NovaRed). Sections were counterstained with hematoxylin for nuclei visualization. TUNEL staining was performed using TUNEL staining kit form Promega (Madison, WI), according to the manufacturer’s instructions. Flow cytometric (FACS) analysis was performed on keratinocytes isolated from newborn pups as described previously (<xref ref-type="bibr" rid="bib34">Tscharntke et al., 2007</xref>) and incubated with APC-conjugated anti-TNFR1 antibody (Biolegend, San Diego, CA) in PBS-BSA buffer, fixed in 4% PFA, followed by acquisition and analysis using FACS Calibur with accompanying software CellQuest (BD Bioscience, San Jose, CA).</p></sec><sec id="s4-4"><title>Apoptosis and cell death assays</title><p>For immunoblotting, the method is described elsewhere (<xref ref-type="bibr" rid="bib8">Ikeda et al., 2011</xref>). Briefly, MEFs (0.05 × 10<sup>6</sup>) were plated on 24-well plates. After 24 hr of subculturing, cells were treated with cycloheximide (CHX) (1 μM) (#C7698; Sigma) or TNF (10 ng/ml) (PeproTech) for the indicated times. Depending on the experimental set-ups, retroviral infection was combined. After the treatment, cells were harvested for SDS-PAGE followed by Western blot analysis. For the FACS analysis (Canto, BD Bioscience, San Jose, CA), the percentage of apoptotic cells was quantified by coupled annexin V antibody (#556419; BD Bioscience) staining and PI uptake. For WST-1 assay on MEFs, 9000 MEFs from wild type and TRADD-deficient mice were seeded in 96-well plates and treated with CHX (10 μg/ml), Necrostatin-1 (25 μM), and Z-VAD-FMK (20 μM) alone or in combination for 20 hr followed by incubation with WST-1 reagent (Roche, Indianapolis, IN) and measurement as per the manufacturer’s instructions. For WST-1 assay on keratinocytes, keratinocytes were isolated as described previously (<xref ref-type="bibr" rid="bib15">Kumari et al., 2013</xref>) and seeded 20,000 cells/well from the indicated genotypes in 96-well plates and stimulated with TNF (20, 50 and 100 ng/ml) in the presence or absence of CHX (1 μg/ml) for 24 hr followed by incubation with WST-1 reagent (Roche) and measurement as per the manufacturer’s instructions. For the caspase-8 activation assay, 50,000 cells/well in a 96-well plate were plated and treated with mTNF, CHX, or Necrostatin-1 for the indicated time. Lysates were used for the determination of caspase-8 activity in a luminescent signal-dependent manner following the manufacturer’s protocol (Promega, caspase-Glo 8 Assay Systems).</p></sec><sec id="s4-5"><title>Immunofluorescence</title><p>Cells were fixed in 4% paraformaldehyde, permeabilized in 0.1%Triton/PBS, blocked in NGS/BSA/0.05%-Triton in PBS and incubated with α-cleaved caspase-3 antibody (Cell Signaling Technologies) followed by incubation with Alexa488 coupled anti-rabbit antibody (Invitrogen). Nuclei were stained by Vectashield mounting media with DAPI (VectorLabs).</p></sec><sec id="s4-6"><title>Lentiviral production</title><p>Lentiviral production and infection was performed according to the Addgene’s pLKO.1 protocol with a minor modification. Briefly, pLKO.1 vector with a packaging and envelope plasmids were transfected into HEK293T cells using Gene Juice (Novagen). After 36 hr of transfection, released lentivirus particles were filtered and used for infection of target MEFs or HaCaT cells using polybrene (4 μg/ml). After 48 hr of infection, cells were selected with puromycin (2 μg/ml). Expression of infected protein was monitored by western blotting.</p></sec><sec id="s4-7"><title>Statistical analysis</title><p>Statistical significance was determined using ANOVA (one-way or two-way) and unpaired or paired Student's <italic>t</italic> test (two-tailed) by Prism 6 software (Graph Pad) or Microsoft Excel (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We would like to acknowledge the HistoLab, the Biooptics, the molecular biology service, the animal house (IMP/IMBA, Vienna, Austria) and C Uthoff-Hachenberg, J Buchholz, E Mahlberg, B Kühnel, D Beier, B Hülser and E Stade for technical support. We also thank all the laboratory members of the Ikeda and Pasparakis groups for active discussion on the project and comments on the manuscript.</p></ack><sec sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>ID: Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf2"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>SK, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>YR, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>JL-M, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>RS, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con5"><p>MR, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con6"><p>SL, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con7"><p>JK, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con8"><p>CM, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con9"><p>ID, Conception and design, Drafting or revising the article</p></fn><fn fn-type="con" id="con10"><p>MP, Conception and design, Drafting or revising the article</p></fn><fn fn-type="con" id="con11"><p>FI, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal procedures were strictly conducted in accordance with the Recommendations and Regulations of the ‘Society for Laboratory Animal Science- GV-SOLAS’ and of the ‘Federation of European Laboratory Animal Science Associations - FELASA’. All of the animals were handled according to the guidelines and approved protocols of 1) European guideline: EUROPEAN CONVENTION FOR THE PROTECTION OF VERTEBRATE ANIMALS USED FOR EXPERIMENTAL AND OTHER SCIENTIFIC PURPOSES, Tierversuchs-Richtlinie (EC) EUROPEAN COUNCIL DIRECTIVE of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes (86/609/EEC), 2) national guidelines: Governing Austrian or German laws, 3) institutional guidelines and 4) approved institutional protocols by local government authorities (IMBA and Cologne University).</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1a"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>SB</given-names></name><name><surname>Kasparcova</surname><given-names>V</given-names></name><name><surname>Hoffman</surname><given-names>S</given-names></name><name><surname>Swift</surname><given-names>B</given-names></name><name><surname>Dare</surname><given-names>L</given-names></name><name><surname>Schaeffer</surname><given-names>M</given-names></name><name><surname>Capriotti</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>M</given-names></name><name><surname>Finger</surname><given-names>J</given-names></name><name><surname>Hughes-Earle</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>PA</given-names></name><name><surname>Kaiser</surname><given-names>WJ</given-names></name><name><surname>Mocarski</surname><given-names>ES</given-names></name><name><surname>Bertin</surname><given-names>J</given-names></name><name><surname>Gough</surname><given-names>PJ</given-names></name></person-group><year>2014</year><article-title>RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice</article-title><source>Journal of Immunology</source><volume>192</volume><fpage>5476</fpage><lpage>5480</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400499</pub-id></element-citation></ref><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>MC</given-names></name><name><surname>Preukschat</surname><given-names>D</given-names></name><name><surname>Welz</surname><given-names>PS</given-names></name><name><surname>van Loo</surname><given-names>G</given-names></name><name><surname>Ermolaeva</surname><given-names>MA</given-names></name><name><surname>Bloch</surname><given-names>W</given-names></name><name><surname>Haase</surname><given-names>I</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name></person-group><year>2011</year><article-title>The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation</article-title><source>Immunity</source><volume>35</volume><fpage>572</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.08.014</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukamp</surname><given-names>P</given-names></name><name><surname>Petrussevska</surname><given-names>RT</given-names></name><name><surname>Breitkreutz</surname><given-names>D</given-names></name><name><surname>Hornung</surname><given-names>J</given-names></name><name><surname>Markham</surname><given-names>A</given-names></name><name><surname>Fusenig</surname><given-names>NE</given-names></name></person-group><year>1988</year><article-title>Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line</article-title><source>The Journal of Cell Biology</source><volume>106</volume><fpage>761</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1083/jcb.106.3.761</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>NJ</given-names></name><name><surname>Chio</surname><suffix>II</suffix></name><name><surname>Lin</surname><given-names>WJ</given-names></name><name><surname>Duncan</surname><given-names>G</given-names></name><name><surname>Chau</surname><given-names>H</given-names></name><name><surname>Katz</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>HL</given-names></name><name><surname>Pike</surname><given-names>KA</given-names></name><name><surname>Hao</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>YW</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>de Pooter</surname><given-names>RF</given-names></name><name><surname>Zúñiga-Pflücker</surname><given-names>JC</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Yeh</surname><given-names>WC</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year>2008</year><article-title>Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>105</volume><fpage>12429</fpage><lpage>12434</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806585105</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermolaeva</surname><given-names>MA</given-names></name><name><surname>Michallet</surname><given-names>MC</given-names></name><name><surname>Papadopoulou</surname><given-names>N</given-names></name><name><surname>Utermohlen</surname><given-names>O</given-names></name><name><surname>Kranidioti</surname><given-names>K</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses</article-title><source>Nature Immunology</source><volume>9</volume><fpage>1037</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1038/ni.1638</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlach</surname><given-names>B</given-names></name><name><surname>Cordier</surname><given-names>SM</given-names></name><name><surname>Schmukle</surname><given-names>AC</given-names></name><name><surname>Emmerich</surname><given-names>CH</given-names></name><name><surname>Rieser</surname><given-names>E</given-names></name><name><surname>Haas</surname><given-names>TL</given-names></name><name><surname>Webb</surname><given-names>AI</given-names></name><name><surname>Rickard</surname><given-names>JA</given-names></name><name><surname>Anderton</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>WW</given-names></name><name><surname>Nachbur</surname><given-names>U</given-names></name><name><surname>Gangoda</surname><given-names>L</given-names></name><name><surname>Warnken</surname><given-names>U</given-names></name><name><surname>Purcell</surname><given-names>AW</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name><name><surname>Walczak</surname><given-names>H</given-names></name></person-group><year>2011</year><article-title>Linear ubiquitination prevents inflammation and regulates immune signalling</article-title><source>Nature</source><volume>471</volume><fpage>591</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/nature09816</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gijbels</surname><given-names>MJ</given-names></name><name><surname>Zurcher</surname><given-names>C</given-names></name><name><surname>Kraal</surname><given-names>G</given-names></name><name><surname>Elliott</surname><given-names>GR</given-names></name><name><surname>HogenEsch</surname><given-names>H</given-names></name><name><surname>Schijff</surname><given-names>G</given-names></name><name><surname>Savelkoul</surname><given-names>HF</given-names></name><name><surname>Bruijnzeel</surname><given-names>PL</given-names></name></person-group><year>1996</year><article-title>Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm)</article-title><source>The American Journal of Pathology</source><volume>148</volume><fpage>941</fpage><lpage>950</lpage></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>TL</given-names></name><name><surname>Emmerich</surname><given-names>CH</given-names></name><name><surname>Gerlach</surname><given-names>B</given-names></name><name><surname>Schmukle</surname><given-names>AC</given-names></name><name><surname>Cordier</surname><given-names>SM</given-names></name><name><surname>Rieser</surname><given-names>E</given-names></name><name><surname>Feltham</surname><given-names>R</given-names></name><name><surname>Vince</surname><given-names>J</given-names></name><name><surname>Warnken</surname><given-names>U</given-names></name><name><surname>Wenger</surname><given-names>T</given-names></name><name><surname>Koschny</surname><given-names>R</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name><name><surname>Walczak</surname><given-names>H</given-names></name></person-group><year>2009</year><article-title>Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction</article-title><source>Molecular Cell</source><volume>36</volume><fpage>831</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.10.013</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>F</given-names></name><name><surname>Deribe</surname><given-names>YL</given-names></name><name><surname>Skanland</surname><given-names>SS</given-names></name><name><surname>Stieglitz</surname><given-names>B</given-names></name><name><surname>Grabbe</surname><given-names>C</given-names></name><name><surname>Franz-Wachtel</surname><given-names>M</given-names></name><name><surname>van Wijk</surname><given-names>SJ</given-names></name><name><surname>Goswami</surname><given-names>P</given-names></name><name><surname>Nagy</surname><given-names>V</given-names></name><name><surname>Terzic</surname><given-names>J</given-names></name><name><surname>Tokunaga</surname><given-names>F</given-names></name><name><surname>Androulidaki</surname><given-names>A</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>K</given-names></name><name><surname>Sundberg</surname><given-names>JP</given-names></name><name><surname>Schaefer</surname><given-names>L</given-names></name><name><surname>Rittinger</surname><given-names>K</given-names></name><name><surname>Macek</surname><given-names>B</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group><year>2011</year><article-title>SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis</article-title><source>Nature</source><volume>471</volume><fpage>637</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/nature09814</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>F</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group><year>2008</year><article-title>Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: beyond the Usual Suspects' review series</article-title><source>EMBO Reports</source><volume>9</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/embor.2008.93</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pitti</surname><given-names>R</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Pham</surname><given-names>VC</given-names></name><name><surname>Lill</surname><given-names>JR</given-names></name><name><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group><year>2009</year><article-title>Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling</article-title><source>Cell</source><volume>137</volume><fpage>721</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.03.015</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanayama</surname><given-names>A</given-names></name><name><surname>Seth</surname><given-names>RB</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Ea</surname><given-names>CK</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name><name><surname>Shaito</surname><given-names>A</given-names></name><name><surname>Chiu</surname><given-names>YH</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year>2004</year><article-title>TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains</article-title><source>Molecular Cell</source><volume>15</volume><fpage>535</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.08.008</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirisako</surname><given-names>T</given-names></name><name><surname>Kamei</surname><given-names>K</given-names></name><name><surname>Murata</surname><given-names>S</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Fukumoto</surname><given-names>H</given-names></name><name><surname>Kanie</surname><given-names>M</given-names></name><name><surname>Sano S</surname></name><name><surname>Tokunaga</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Iwai</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>A ubiquitin ligase complex assembles linear polyubiquitin chains</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>4877</fpage><lpage>4887</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601360</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>The ubiquitin code</article-title><source>Annual Review of Biochemistry</source><volume>81</volume><fpage>203</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060310-170328</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulathu</surname><given-names>Y</given-names></name><name><surname>Akutsu</surname><given-names>M</given-names></name><name><surname>Bremm</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name></person-group><year>2009</year><article-title>Two-sided ubiquitin binding explains specificity of the TAB2 NZF domain</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>16</volume><fpage>1328</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1731</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>S</given-names></name><name><surname>Bonnet</surname><given-names>MC</given-names></name><name><surname>Ulvmar</surname><given-names>MH</given-names></name><name><surname>Wolk</surname><given-names>K</given-names></name><name><surname>Karagianni</surname><given-names>N</given-names></name><name><surname>Witte</surname><given-names>E</given-names></name><name><surname>Uthoff-Hachenberg</surname><given-names>C</given-names></name><name><surname>Renauld</surname><given-names>JC</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><name><surname>Toftgard</surname><given-names>R</given-names></name><name><surname>Sabat</surname><given-names>R</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Haase</surname><given-names>I</given-names></name></person-group><year>2013</year><article-title>Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice</article-title><source>Immunity</source><volume>39</volume><fpage>899</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.10.009</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EW</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Ahn</surname><given-names>YH</given-names></name><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>Jeong</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Ro</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Park</surname><given-names>EJ</given-names></name><name><surname>Chun</surname><given-names>KH</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><year>2012</year><article-title>Ubiquitination and degradation of the FADD adaptor protein regulate death receptor-mediated apoptosis and necroptosis</article-title><source>Nature Communications</source><volume>3</volume><fpage>978</fpage><pub-id pub-id-type="doi">10.1038/ncomms1981</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Sundberg</surname><given-names>JP</given-names></name></person-group><year>2011</year><article-title>SHARPIN regulates mitochondria-dependent apoptosis in keratinocytes</article-title><source>Journal of Dermatological Science</source><volume>63</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2011.04.012</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mc Guire</surname><given-names>C</given-names></name><name><surname>Volckaert</surname><given-names>T</given-names></name><name><surname>Wolke</surname><given-names>U</given-names></name><name><surname>Sze</surname><given-names>M</given-names></name><name><surname>de Rycke</surname><given-names>R</given-names></name><name><surname>Waisman</surname><given-names>A</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Beyaert</surname><given-names>R</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>van Loo</surname><given-names>G</given-names></name></person-group><year>2010</year><article-title>Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination</article-title><source>Journal of Immunology</source><volume>185</volume><fpage>7646</fpage><lpage>7653</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000930</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michallet</surname><given-names>MC</given-names></name><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Ermolaeva</surname><given-names>MA</given-names></name><name><surname>Vazquez</surname><given-names>J</given-names></name><name><surname>Rebsamen</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>J</given-names></name><name><surname>Poeck</surname><given-names>H</given-names></name><name><surname>Bscheider</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>G</given-names></name><name><surname>König</surname><given-names>M</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year>2008</year><article-title>TRADD protein is an essential component of the RIG-like helicase antiviral pathway</article-title><source>Immunity</source><volume>28</volume><fpage>651</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.013</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><year>2004</year><article-title>Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>1464</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.4.1464-1469.2004</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Alexopoulou</surname><given-names>L</given-names></name><name><surname>Douni</surname><given-names>E</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name></person-group><year>1996a</year><article-title>Tumour necrosis factors in immune regulation: everything that's interesting is...new!</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>7</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(96)00031-7</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Alexopoulou</surname><given-names>L</given-names></name><name><surname>Episkopou</surname><given-names>V</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name></person-group><year>1996b</year><article-title>Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response</article-title><source>The Journal of Experimental Medicine</source><volume>184</volume><fpage>1397</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1084/jem.184.4.1397</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Courtois</surname><given-names>G</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Schmidt-Supprian</surname><given-names>M</given-names></name><name><surname>Nenci</surname><given-names>A</given-names></name><name><surname>Toksoy</surname><given-names>A</given-names></name><name><surname>Krampert</surname><given-names>M</given-names></name><name><surname>Goebeler</surname><given-names>M</given-names></name><name><surname>Gillitzer</surname><given-names>R</given-names></name><name><surname>Israel</surname><given-names>A</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Haase</surname><given-names>I</given-names></name></person-group><year>2002</year><article-title>TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2</article-title><source>Nature</source><volume>417</volume><fpage>861</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1038/nature00820</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Kousteni</surname><given-names>S</given-names></name><name><surname>Peschon</surname><given-names>J</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name></person-group><year>2000</year><article-title>Tumor necrosis factor and the p55TNF receptor are required for optimal development of the marginal sinus and for migration of follicular dendritic cell precursors into splenic follicles</article-title><source>Cellular Immunology</source><volume>201</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1006/cimm.2000.1636</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Matsuyama</surname><given-names>T</given-names></name><name><surname>Kundig</surname><given-names>TM</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Kishihara</surname><given-names>K</given-names></name><name><surname>Shahinian</surname><given-names>A</given-names></name><name><surname>Wiegmann</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Krönke</surname><given-names>M</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year>1993</year><article-title>Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection</article-title><source>Cell</source><volume>73</volume><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90134-C</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pobezinskaya</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Choksi</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>MJ</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><year>2008</year><article-title>The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors</article-title><source>Nature Immunology</source><volume>9</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1038/ni.1639</pub-id></element-citation></ref><ref id="bib26a"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickard</surname><given-names>JA</given-names></name><name><surname>Anderton</surname><given-names>H</given-names></name><name><surname>Etemadi</surname><given-names>N</given-names></name><name><surname>Nachbur</surname><given-names>U</given-names></name><name><surname>Darding</surname><given-names>M</given-names></name><name><surname>Peltzer</surname><given-names>N</given-names></name><name><surname>Lalaoui</surname><given-names>N</given-names></name><name><surname>Lawlor</surname><given-names>KE</given-names></name><name><surname>Vanyai</surname><given-names>H</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Bankovacki</surname><given-names>A</given-names></name><name><surname>Gangoda</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>WW</given-names></name><name><surname>Corbin</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Mocarski</surname><given-names>E</given-names></name><name><surname>Murphy</surname><given-names>JM</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Voss</surname><given-names>AK</given-names></name><name><surname>Vaux</surname><given-names>DL</given-names></name><name><surname>Kaiser</surname><given-names>WJ</given-names></name><name><surname>Walczak</surname><given-names>H</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name></person-group><year>2014</year><article-title>Cell death drives TNFR1-dependent <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> dermatitis and multi-organ pathology</article-title><source>eLife</source><comment>In press</comment><pub-id pub-id-type="doi">10.7554/eLife.03464</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>A</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Yamagata</surname><given-names>A</given-names></name><name><surname>Fukai</surname><given-names>S</given-names></name></person-group><year>2009</year><article-title>Structural basis for specific recognition of Lys 63-linked polyubiquitin chains by NZF domains of TAB2 and TAB3</article-title><source>The EMBO Journal</source><volume>28</volume><fpage>3903</fpage><lpage>3909</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.345</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmukle</surname><given-names>AC</given-names></name><name><surname>Walczak</surname><given-names>H</given-names></name></person-group><year>2012</year><article-title>No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity</article-title><source>Journal of Cell Science</source><volume>125</volume><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1242/jcs.091793</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seymour</surname><given-names>RE</given-names></name><name><surname>Hasham</surname><given-names>MG</given-names></name><name><surname>Cox</surname><given-names>GA</given-names></name><name><surname>Shultz</surname><given-names>LD</given-names></name><name><surname>Hogenesch</surname><given-names>H</given-names></name><name><surname>Roopenian</surname><given-names>DC</given-names></name><name><surname>Sundberg</surname><given-names>JP</given-names></name></person-group><year>2007</year><article-title>Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis</article-title><source>Genes and Immunity</source><volume>8</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6364403</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stieglitz</surname><given-names>B</given-names></name><name><surname>Morris-Davies</surname><given-names>AC</given-names></name><name><surname>Koliopoulos</surname><given-names>MG</given-names></name><name><surname>Christodoulou</surname><given-names>E</given-names></name><name><surname>Rittinger</surname><given-names>K</given-names></name></person-group><year>2012</year><article-title>LUBAC synthesizes linear ubiquitin chains via a thioester intermediate</article-title><source>EMBO Reports</source><volume>13</volume><fpage>840</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1038/embor.2012.105</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stieglitz</surname><given-names>B</given-names></name><name><surname>Rana</surname><given-names>RR</given-names></name><name><surname>Koliopoulos</surname><given-names>MG</given-names></name><name><surname>Morris-Davies</surname><given-names>AC</given-names></name><name><surname>Schaeffer</surname><given-names>V</given-names></name><name><surname>Christodoulou</surname><given-names>E</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>NR</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name><name><surname>Rittinger</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>Structural basis for ligase-specific conjugation of linear ubiquitin chains by HOIP</article-title><source>Nature</source><volume>503</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature12638</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>F</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Nakahara</surname><given-names>M</given-names></name><name><surname>Saeki</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Iwai</surname><given-names>K</given-names></name></person-group><year>2011</year><article-title>SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex</article-title><source>Nature</source><volume>471</volume><fpage>633</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/nature09815</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>F</given-names></name><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Saeki</surname><given-names>Y</given-names></name><name><surname>Satomi</surname><given-names>Y</given-names></name><name><surname>Kirisako</surname><given-names>T</given-names></name><name><surname>Kamei</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Murata</surname><given-names>S</given-names></name><name><surname>Yamaoka</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Takao</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Iwai</surname><given-names>K</given-names></name></person-group><year>2009</year><article-title>Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation</article-title><source>Nature Cell Biology</source><volume>11</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/ncb1821</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tscharntke</surname><given-names>M</given-names></name><name><surname>Pofahl</surname><given-names>R</given-names></name><name><surname>Chrostek-Grashoff</surname><given-names>A</given-names></name><name><surname>Smyth</surname><given-names>N</given-names></name><name><surname>Niessen</surname><given-names>C</given-names></name><name><surname>Niemann</surname><given-names>C</given-names></name><name><surname>Hartwig</surname><given-names>B</given-names></name><name><surname>Herzog</surname><given-names>V</given-names></name><name><surname>Klein</surname><given-names>HW</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Brakebusch</surname><given-names>C</given-names></name><name><surname>Haase</surname><given-names>I</given-names></name></person-group><year>2007</year><article-title>Impaired epidermal wound healing in vivo upon inhibition or deletion of Rac1</article-title><source>Journal of Cell Science</source><volume>120</volume><fpage>1480</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1242/jcs.03426</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hauwermeiren</surname><given-names>F</given-names></name><name><surname>Armaka</surname><given-names>M</given-names></name><name><surname>Karagianni</surname><given-names>N</given-names></name><name><surname>Kranidioti</surname><given-names>K</given-names></name><name><surname>Vandenbroucke</surname><given-names>RE</given-names></name><name><surname>Loges</surname><given-names>S</given-names></name><name><surname>Van Roy</surname><given-names>M</given-names></name><name><surname>Staelens</surname><given-names>J</given-names></name><name><surname>Puimège</surname><given-names>L</given-names></name><name><surname>Palagani</surname><given-names>A</given-names></name><name><surname>Berghe</surname><given-names>WV</given-names></name><name><surname>Victoratos</surname><given-names>P</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Libert</surname><given-names>C</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name></person-group><year>2013</year><article-title>Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>2590</fpage><lpage>2603</lpage><pub-id pub-id-type="doi">10.1172/JCI65624</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varfolomeev</surname><given-names>E</given-names></name><name><surname>Goncharov</surname><given-names>T</given-names></name><name><surname>Fedorova</surname><given-names>AV</given-names></name><name><surname>Dynek</surname><given-names>JN</given-names></name><name><surname>Zobel</surname><given-names>K</given-names></name><name><surname>Deshayes</surname><given-names>K</given-names></name><name><surname>Fairbrother</surname><given-names>WJ</given-names></name><name><surname>Vucic</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>24295</fpage><lpage>24299</lpage><pub-id pub-id-type="doi">10.1074/jbc.C800128200</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhelst</surname><given-names>K</given-names></name><name><surname>Carpentier</surname><given-names>I</given-names></name><name><surname>Beyaert</surname><given-names>R</given-names></name></person-group><year>2011</year><article-title>Regulation of TNF-induced NF-kappaB activation by different cytoplasmic ubiquitination events</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>22</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2011.11.002</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinlich</surname><given-names>R</given-names></name><name><surname>Oberst</surname><given-names>A</given-names></name><name><surname>Dillon</surname><given-names>CP</given-names></name><name><surname>Janke</surname><given-names>LJ</given-names></name><name><surname>Milasta</surname><given-names>S</given-names></name><name><surname>Lukens</surname><given-names>JR</given-names></name><name><surname>Rodriguez</surname><given-names>DA</given-names></name><name><surname>Gurung</surname><given-names>P</given-names></name><name><surname>Savage</surname><given-names>C</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><year>2013</year><article-title>Protective roles for caspase-8 and cFLIP in adult homeostasis</article-title><source>Cell Reports</source><volume>5</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.08.045</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wertz</surname><given-names>IE</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><year>2008</year><article-title>Ubiquitin-mediated regulation of TNFR1 signaling</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>19</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2008.04.014</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Conze</surname><given-names>DB</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ying</surname><given-names>SX</given-names></name><name><surname>Hanover</surname><given-names>JA</given-names></name><name><surname>Ashwell</surname><given-names>JD</given-names></name></person-group><year>2005</year><article-title>TNF-alpha induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>1886</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600649</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.03422.018</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shao</surname><given-names>Feng</given-names></name><role>Reviewing editor</role><aff><institution>National Institute of Biological Sciences</institution>, <country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for sending your work entitled “Sharpin prevents TNFR1-induced keratinocyte apoptosis and skin inflammation via linear ubiquitination of FADD” for consideration at <italic>eLife</italic>. Your article has been favorably evaluated by Tadatsugu Taniguchi (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.</p><p>The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.</p><p>In this manuscript, Kumari et al. employ a variety of genetically modified mice and nicely demonstrate the FADD and TRADD-mediated TNF-induced apoptosis in epidermal keratinocytes is mainly responsible for skin inflammation and dermatitis in Sharpin-deficient cpdm mice. They also show that RIP3-mediated necroptosis only plays a minor role in the skin pathology, but the absence of TNFR1 and RIP3 can significantly (but not completely) block liver and lung inflammation as well as splenomegaly in Sharpin-deficient mice. Secondly, they show that Sharpin-deficient MEF cells are more sensitive to TNF induction of apoptosis and FADD appears to play an important role in this process. Thirdly, the rest of the manuscript tries to suggest that linear ubiquitination of FADD by Sharpin and LUBAC negatively regulates TNF-induced apoptosis, which may be the mechanism underlying the increase sensitivity of Sharpin deficiency to TNF-induced apoptosis. Overall, the first part of the story provides strong data and important insights into the mechanism of skin and multiple organ inflammation observed in cpdm mice. These, together with the second part of the story, nicely demonstrate the physiological function of Sharpin and likely also the LUBAC complex in negatively regulating apoptosis downstream of the death receptors. The third part aimed at providing a thorough biochemical mechanism for the apoptosis inhibition function of Sharpin is rather weak and in fact not essential for the story that is already pretty informative. Therefore, the authors should consider addressing the following comments when revising their manuscript.</p><p>Major comments:</p><p>1) For <xref ref-type="fig" rid="fig2 fig4 fig5">Figures 2A, 2B, 4A, 4B, 5A and 5B</xref>, the authors should include littermate mice as the appropriate controls.</p><p>2) The authors provide strong in vitro data that LUBAC can ubiquitinate FADD (<xref ref-type="fig" rid="fig9">Figure 9B</xref>) and that Sharpin but not HOIL-1l/HOIP can bind to FADD directly. However, the functional data supporting that ubiquitination of FADD by LUBAC suppresses TNF-induced apoptosis is rather weak, indirect and not sufficiently convincing. The most important piece of data is the FADD K0 mutant rescue assay in <xref ref-type="fig" rid="fig9">Figure 9D</xref>, in which the difference of apoptosis induction (PARP and caspase-3 cleavage) between WT and FADD K0 complementation is very subtle and not sufficient to justify the conclusion. The FADD-ubiquitin chimera experiment is difficult to interpret and should be removed from the manuscript, particularly in the absence of observing FADD ubiquitination in vivo.</p><p>The manuscript contains sufficient new information from <xref ref-type="fig" rid="fig1 fig2 fig3 fig4 fig5 fig6 fig7">Figure 1-7</xref>; starting from characterizing the phenotype using various genetically modified mice to the demonstration that FADD is responsible for the increased apoptosis sensitivity to TNF stimulation. There is no need of defining the substrate of LUBAC involved in this process. If the authors really want to make the point here, they need to show in vivo linear ubiquitination of endogenous FADD upon TNF stimulation, ideally in keratinocytes, and this ubiquitination is absent in Sharpincpdm/cdpm cells.</p><p>3) In view of the recent paper by Berger et al (JI, June 2014), cell death observed in the Sharpin deficient mice/cells could be expected to be RIPK1 kinase dependent. Therefore, the authors should use another cell model rather than the TNF/CHX treatment in MEFs, since this kills in a RIPK1 kinase-independent way and may not reflect the in vivo situation. In fact, keratinocytes are much more appropriate, for demonstrating that increased apoptosis in the skin is key to the development of skin inflammation and dermatitis in cpdm mice. The authors should examine whether TNF is sufficient to induce apoptosis in primary keratinocytes derived from cpdm mice and compare the cell death of WT keratinocytes. The authors then can further examine whether FADD and TRADD (individually or double) deficiency can block the sensitivity of Sharpincpdm/cdpm keratinocytes. This can either be done by using the mice they already have or siRNA knockdown of FADD and TRADD. The authors argued that Sharpin prevents apoptosis independently from its role in NF-kB pathway and this should be further examined other relevant cellular systems in which the Sharpin deficient cells are killed by TNF without adding CHX.</p><p>4) At the cellular level, Sharpin-deficiency sensitizes the cells to TNF-induced apoptosis. The authors should examine whether the apoptosis is RIPK1 kinase-dependent. They can also look at the RIPK1-containing complexes and compare with that in the presence of Sharpin.</p><p>5) Sharpin is a component of the LUBAC complex. Another important question that the authors should address is whether Sharpin really functions through LUBAC in inhibiting TNF-induced apoptosis. Therefore, the authors should examine whether other LUBAC components are involved in the observed cellular apoptosis phenotypes, ideally in keratinocytes.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.03422.019</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) For</italic> <xref ref-type="fig" rid="fig2 fig4 fig5"><italic>Figures 2A, 2B, 4A, 4B, 5A and 5B</italic></xref><italic>, the authors should include littermate mice as the appropriate controls</italic>.</p><p>Due to the complex breeding schemes required for the generation of some of the mouse lines described, it was not always possible to obtain littermates with all possible control genotypes. Whenever possible, we have made an effort to include littermate controls, but this was not always feasible. However, we would like to point out that the variability we observed in the phenotype of the cpdm mice was also seen within litters. Even in breeding of cpdm heterozygous mice without any additional alleles we often observed that littermate <italic>Sharpin</italic> <sup><italic>cpdm/cpdm</italic></sup> mice exhibited variability in the onset of the skin lesions, with some mice starting to show lesions as early as at 9 weeks of age and some as late as 12 weeks. Because of this variability in the onset of the phenotype even within the same litter, we have selected representative mice to show for each genotype that correspond to the average stage of disease observed among a large number of individual animals examined.</p><p>Specifically, we used the following controls for each of the lines:</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p>- <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/<italic>Tnfr1f</italic><sup><italic>l/fl</italic></sup><italic>/K14Cre</italic> line: For this line, we have used littermates that are cpdm/cpdm, <italic>Tnfr1</italic><sup>fl/fl</sup> but not expressing the K14Cre transgene. Littermate control for this line is added in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</p><p>- <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> /<italic>Tnfr1</italic><sup><italic>-/-</italic></sup> line: By breeding double heterozygous mice the probability of obtaining <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/<italic>Tnfr1</italic><sup>wt/wt</sup> or <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/<italic>Tnfr1</italic><sup>-/-</sup> mice is 1/16. By considering an average number of 6-7 pups per litter, the probability to have one <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> /<italic>Tnfr1</italic><sup>wt/wt</sup> and one <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/<italic>Tnfr1</italic><sup>-/-</sup> mouse within the same litter is very low. In order to obtain the number of mice we needed for a comprehensive analysis of the phenotype we also used breeding of heterozygous cpdm mice that were homozygous <italic>Tnfr1</italic><sup>-/-</sup> and compared the resulting mice to <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> or <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/<italic>Tnfr1f</italic><sup><italic>l/fl</italic></sup> mice from other breedings.</p><p>- <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> /<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>-/-</italic></sup> line: For this line we compared littermates that are K14Cre positive (<italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/FADD<sup>E-KO</sup>/<italic>Ripk3</italic><sup><italic>-/-</italic></sup>) that are FADD-deficient in keratinocytes with K14Cre negative (<italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>/<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>/<italic>Ripk3</italic><sup><italic>-/-</italic></sup>) that express FADD in keratinocytes.</p><p>Therefore, we compared the effect of double FADD/RIPK3 knockout to that of single RIPK3 knockout. In addition, we have now added littermate controls for <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> /<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup><italic>-/-</italic></sup> line (<italic>Sharpin</italic><sup><italic>wt/wt</italic></sup>/<italic>Fadd</italic><sup><italic>fl/wt</italic></sup>;<italic>Ripk3</italic><sup><italic>-/-</italic></sup>) in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. To have the best possible matched controls, we have replaced some of the pictures of the old figures. In <xref ref-type="fig" rid="fig5">Figure 5A</xref> <italic>(left most panel),</italic> histology of liver and spleen has been replaced. In <xref ref-type="fig" rid="fig5">Figure 5B</xref>, the macroscopic spleen picture has been replaced with spleen picture of littermate controls. Wherever possible, in the new version of the figures or figure legends, we have stated the exact genotype of the mouse used in each figure.</p><p><italic>2) The authors provide strong in vitro data that LUBAC can ubiquitinate FADD (</italic><xref ref-type="fig" rid="fig9"><italic>Figure 9B</italic></xref><italic>) and that Sharpin but not HOIL-1l/HOIP can bind to FADD directly. However, the functional data supporting that ubiquitination of FADD by LUBAC suppresses TNF-induced apoptosis is rather weak, indirect and not sufficiently convincing. The most important piece of data is the FADD K0 mutant rescue assay in</italic> <xref ref-type="fig" rid="fig9"><italic>Figure 9D</italic></xref><italic>, in which the difference of apoptosis induction (PARP and caspase-3 cleavage) between WT and FADD K0 complementation is very subtle and not sufficient to justify the conclusion</italic>.</p><p>We agree with the reviewers and removed FADD-ubiquitination data, interaction assay of FADD and LUBAC components, and FADD K0 data and the related panels.</p><p><italic>The FADD-ubiquitin chimera experiment is difficult to interpret and should be removed from the manuscript, particularly in the absence of observing FADD ubiquitination in vivo</italic>.</p><p>We agree with the reviewers and removed FADD-ubiquitin chimera data.</p><p><italic>The manuscript contains sufficient new information from</italic> <xref ref-type="fig" rid="fig1 fig2 fig3 fig4 fig5 fig6 fig7"><italic>Figure 1-7</italic></xref><italic>; starting from characterizing the phenotype using various genetically modified mice to the demonstration that FADD is responsible for the increased apoptosis sensitivity to TNF stimulation. There is no need of defining the substrate of LUBAC involved in this process. If the authors really want to make the point here, they need to show in vivo linear ubiquitination of endogenous FADD upon TNF stimulation, ideally in keratinocytes, and this ubiquitination is absent in Sharpincpdm/cdpm cells</italic>.</p><p>We thank the reviewers for this suggestion and reformatted the manuscript by focusing on the role of FADD in TNF-mediated apoptosis of sharpin-deficient cells without its ubiquitination. Therefore, panels which related to FADD ubiquitination, in which linear-ubiquitin chain interacter ABIN1 was tested were removed.</p><p><italic>3) In view of the recent paper by Berger et al (JI, June 2014), cell death observed in the Sharpin deficient mice/cells could be expected to be RIPK1 kinase dependent. Therefore, the authors should use another cell model rather than the TNF/CHX treatment in MEFs, since this kills in a RIPK1 kinase-independent way and may not reflect the in vivo situation. In fact, keratinocytes are much more appropriate, for demonstrating that increased apoptosis in the skin is key to the development of skin inflammation and dermatitis in cpdm mice. The authors should examine whether TNF is sufficient to induce apoptosis in primary keratinocytes derived from cpdm mice and compare the cell death of WT keratinocytes</italic>.</p><p>We agree with the reviewers that addressing the role of Sharpin in TNF-induced death of keratinocytes is more relevant to the <italic>in vivo</italic> studies. To assess TNF-induced death we prepared primary keratinocytes lacking sharpin, sharpin and RIPK3, sharpin and TNFR1 and sharpin, RIPK3 and FADD as well as control cells from littermates as shown in <xref ref-type="fig" rid="fig9">Figure 9A</xref>. We treated these primary keratinocytes with increasing concentration of TNF (20, 50, 100ng/ml) alone or together with cycloheximide (CHX) (1 µg/ml) and analyzed their viability 24 hours after stimulation using the WST-1 assay. We found that in the presence of CHX, TNF induces the death of about 80% of sharpin-deficient keratinocytes compared to about 40% of control cells (new <xref ref-type="fig" rid="fig9">Figure 9A</xref>). TNF+CHX-induced death was not inhibited by RIPK3 deficiency but was fully prevented by lack of TNFR1 or double FADD/RIPK3 deficiency, showing that in the presence of CHX, sharpin deficiency sensitizes keratinocytes to TNF induced FADD-dependent apoptosis. However, in the absence of CHX, we observed that TNF treatment (only at the higher concentration 50 and 100 ng/ml) reduced the viability of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> keratinocytes by about 8-10% compared to heterozygous or wild type (<italic>Sharpin</italic><sup><italic>cpdm/wt</italic></sup> or <italic>Sharpin</italic><sup><italic>wt/wt</italic></sup> ) control kearatinocytes. This effect of TNF was too weak to provide robust data allowing the comparison between the different genotypes, as a reduction of viability by 8-10% is within the range of the normal variability observed in this assay using primary keratinocytes. We conclude that while TNF clearly induces apoptosis of sharpin-deficient keratinocytes <italic>in vivo</italic> that is responsible for skin inflammation in cpdm mice, in primary keratinocyte cultures TNF stimulation does not induce considerable amount of cell death in the absence of CHX to allow reliable quantification of the effect. It is possible that the <italic>in vivo</italic> context and the keratinocyte differentiation status are responsible for the difference between the epidermal keratinocytes <italic>in vivo</italic> and the primary cultured cells.</p><p>To bypass this problem, in parallel we performed experiments in a human keratinocyte cell line, HaCaT cells, in the presence or absence of Sharpin by knockdown. We observed that TNF alone induced mildly elevated apoptosis in Sharpin-knockdown HaCaT cells compared to control cells. Although the increase in cell death was in the range observed for the primary cells, we were able to quantify this difference reliable using Annexin V staining and measurement of caspase-8 activity (new <xref ref-type="fig" rid="fig8">Figure 8A-C</xref>). These results are similar to what we observed before in Sharpin deficient MEFs (new <xref ref-type="fig" rid="fig7">Figure 7E, F</xref>), and this effect was further enhanced in the presence of CHX. To address the role of RIPK1 kinase activity, we treated cells with TNF in the presence of the RIPK1 kinase inhibitor Necrostatin -1 (Nec-1). As shown in new <xref ref-type="fig" rid="fig8">Figure 8D</xref>, in the presence of Nec-1, we observed reduction of caspase-8 activity in sharpin-deficient cells. This result shows a partial inhibition of TNF-induced apoptosis in the presence of Nec-1, suggesting a role of RIPK1 in this signaling pathway as indicated by the <italic>in vivo</italic> result from Berger et al. (2014).</p><p><italic>The authors then can further examine whether FADD and TRADD (individually or double) deficiency can block the sensitivity of Sharpincpdm/cdpm keratinocytes. This can either be done by using the mice they already have or siRNA knockdown of FADD and TRADD. The authors argued that Sharpin prevents apoptosis independently from its role in NF-kB pathway and this should be further examined other relevant cellular systems in which the Sharpin deficient cells are killed by TNF without adding CHX</italic>.</p><p>To examine whether FADD and TRADD deficiency can block the TNF-induced sensitivity of Sharpin-deficient HaCaT cells, we generated knockdown HaCaT cells lacking Sharpin+FADD or Sharpin+TRADD and examined TNF -induced apoptosis with and without CHX (new <xref ref-type="fig" rid="fig9">Figure 9B-G</xref>). We observed that both FADD and TRADD deficiencies suppressed TNF-induced apoptosis (with or without CHX) in Sharpin knockdown HaCaT cells, which further indicates that enhanced sensitivity of sharpin-deficient keratinocytes to TNF is FADD and TRADD- dependent. It was an identical case with FADD knockdown in Sharpin deficient MEFs (<xref ref-type="fig" rid="fig9">Figure 9C</xref>).</p><p>As mentioned in our response to the previous comment, to address the role of FADD and RIPK3 in TNF-induced death of primary keratinocytes, we isolated primary keratinocytes from <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> <italic>or Sharpin</italic><sup><italic>cpdm/wt</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup>-/-</sup> lines, stimulated with TNF alone or with TNF + CHX and analyzed their viability using the WST-1 assay. Interestingly, the increased sensitivity of <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> keratinocytes to TNF+CHX was fully rescued in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;FADD<sup>E-KO</sup>;<italic>Ripk3</italic><sup>-/</sup> keratinocytes. However keratinocytes obtained from <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup>;<italic>Fadd</italic><sup><italic>fl/fl</italic></sup>;<italic>Ripk3</italic><sup>-/-</sup> mice showed similar response to TNF+CHX as observed in <italic>Sharpin</italic><sup><italic>cpdm/cpdm</italic></sup> keratinocytes (new <xref ref-type="fig" rid="fig9">Figure 9A</xref>). Therefore, double FADD/RIPK3 deficiency fully prevented TNF+CHX induced apoptosis of Sharpin-deficient keratinocytes while RIPK3 deficiency alone had no effect, confirming that TNF kills Sharpin-deficient keratinocytes primarily due to FADD-mediated apoptosis (new <xref ref-type="fig" rid="fig9">Figure 9A</xref>). However, as discussed above, TNF treatment alone had a minor effect in inducing the death of Sharpin-deficient primary keratinocytes, which we could not quantify reliably to allow comparison between the different genotypes. Based on these results, we cannot reliably conclude whether the role of Sharpin in preventing TNF-induced apoptosis is independent of NF-κB activity. It is likely that Sharpin prevents TNF-induced apoptosis by both NF-κB dependent and independent activities.</p><p><italic>4) At the cellular level, Sharpin-deficiency sensitizes the cells to TNF-induced apoptosis. The authors should examine whether the apoptosis is RIPK1 kinase-dependent. They can also look at the RIPK1-containing complexes and compare with that in the presence of Sharpin</italic>.</p><p>As we mentioned above (#3), based on the effect of RIPK1 inhibitor Nec-1 on TNF-treated Sharpin deficient HaCaT cells, RIPK1 is suggested to be involved in Sharpin-dependent apoptosis regulation in keratinocytes. We agree that to understand the RIPK1 complex with and without Sharpin in keratinocytes is important and interesting. Unfortunately, we could not observe the RIP1-containing complex with LUBAC components by performing co-IP using anti-RIP1 antibody, with TNF+zVAD-treated HaCaT cells, leaving out the question whether Sharpin affects the RIP1-complex formation.</p><p><italic>5) Sharpin is a component of the LUBAC complex. Another important question that the authors should address is whether Sharpin really functions through LUBAC in inhibiting TNF-induced apoptosis. Therefore, the authors should examine whether other LUBAC components are involved in the observed cellular apoptosis phenotypes, ideally in keratinocytes</italic>.</p><p>We agree that it is an important point. To address this issue, we generated HOIP-knockdown HaCaT keratinocyte cell line using shRNA. TNF alone or TNF+CHX induced increased apoptosis of HaCaT cells (lacking HOIP), suggesting an important role of the LUBAC complex in the preventing TNF induced apoptosis in keratinocytes. New data are added in <xref ref-type="fig" rid="fig8s1">Figure 8–figure supplement 1</xref>.</p></body></sub-article></article>